Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
The symptoms of Kaposi Sarcoma include patches that are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.
The Kaposi Sarcoma pipeline market research report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects.
Kaposi Sarcoma Pipeline Products Market Segmentation by Targets
The key targets in the Kaposi Sarcoma pipeline products market are Tubulin, Programmed Cell Death Protein 1, Cells Expressing Fibronectin, Cells Expressing Macrophage Mannose Receptor 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Cytotoxic T Lymphocyte Protein 4, Ephrin Type B Receptor 4, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha, Indoleamine 2,3 Dioxygenase 1, and others.
Kaposi Sarcoma Pipeline Products Market Analysis by Targets
For more target insights into the Kaposi Sarcoma pipeline products market, download a free report sample
Kaposi Sarcoma Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Kaposi Sarcoma pipeline products market are Tubulin Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Fibronectin, Cytotoxic To Cells Expressing Macrophage Mannose Receptor 1, Ephrin Type B Receptor 4 Inhibitor, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha Agonist, Indoleamine 2,3 Dioxygenase 1 Activator, and others.
Kaposi Sarcoma Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Kaposi Sarcoma pipeline products market, download a free report sample
Kaposi Sarcoma Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Kaposi Sarcoma pipeline products market are intravenous, subcutaneous, intralesional, intratumor, intravesical, oral, intraperitoneal, intramuscular, intrapleural, intrathecal, and others.
Kaposi Sarcoma Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Kaposi Sarcoma pipeline products market, download a free report sample
Kaposi Sarcoma Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Kaposi Sarcoma pipeline products market are small molecule, fusion protein, monoclonal antibody, synthetic peptide, oncolytic virus, polysaccharide, protein, and recombinant protein.
Kaposi Sarcoma Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Kaposi Sarcoma pipeline products market, download a free report sample
Kaposi Sarcoma Pipeline Products Market – Competitive Landscape
Some of the leading companies in the Kaposi Sarcoma pipeline products market are Merck KGaA, Amgen Inc, Aphios Corp, Bristol-Myers Squibb Co, Cannabis Science Inc, Cello Therapeutics Inc, Codiak BioSciences Inc, DAE HWA Pharmaceutical Co Ltd, Eli Lilly and Co, and Galephar Pharmaceutical Research Inc.
Kaposi Sarcoma Pipeline Products Market Analysis by Companies
To know more about the leading players in the Kaposi Sarcoma pipeline products market, download a free report sample
Kaposi Sarcoma Pipeline Products Market Report Overview
| Key Targets | Tubulin, Programmed Cell Death Protein 1, Cells Expressing Fibronectin, Cells Expressing Macrophage Mannose Receptor 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Cytotoxic T Lymphocyte Protein 4, Ephrin Type B Receptor 4, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha, Indoleamine 2,3 Dioxygenase 1, and Others |
| Key Mechanisms of Action | Tubulin Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Fibronectin, Cytotoxic To Cells Expressing Macrophage Mannose Receptor 1, Ephrin Type B Receptor 4 Inhibitor, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha Agonist, Indoleamine 2,3 Dioxygenase 1 Activator, and Others |
| Key Routes of Administration | Intravenous, Subcutaneous, Intralesional, Intratumor, Intravesical, Oral, Intraperitoneal, Intramuscular, Intrapleural, Intrathecal, and Others |
| Key Molecule Type | Small Molecule, Fusion Protein, Monoclonal Antibody, Synthetic Peptide, Oncolytic Virus, Polysaccharide, Protein, and Recombinant Protein |
| Leading Companies | Merck KGaA, Amgen Inc, Aphios Corp, Bristol-Myers Squibb Co, Cannabis Science Inc, Cello Therapeutics Inc, Codiak BioSciences Inc, DAE HWA Pharmaceutical Co Ltd, Eli Lilly and Co, and Galephar Pharmaceutical Research Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Aphios Corp
Bristol-Myers Squibb Co
Cannabis Science Inc
Cello Therapeutics Inc
Codiak BioSciences Inc
DAE HWA Pharmaceutical Co Ltd
Eli Lilly and Co
Galephar Pharmaceutical Research Inc
Genexine Inc
Kang Litai Pharmaceutical Co Ltd
LATITUDE Pharmaceuticals Inc
LipoSeuticals Inc
Macrophage Therapeutics Inc
Merck & Co Inc
Merck KGaA
Nammi Therapeutics Inc
Ono Pharmaceutical Co Ltd
Philogen SpA
Sanofi.
Seven and Eight Biopharmaceuticals Corp
Statera Biopharma Inc
Tumorend LLC
VasGene Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Kaposi Sarcoma pipeline products market?
The key targets in the Kaposi Sarcoma pipeline products market are Tubulin, Programmed Cell Death Protein 1, Cells Expressing Fibronectin, Cells Expressing Macrophage Mannose Receptor 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Cytotoxic T Lymphocyte Protein 4, Ephrin Type B Receptor 4, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha, Indoleamine 2,3 Dioxygenase 1, and others.
-
What are the key mechanisms of action in the Kaposi Sarcoma pipeline products market?
The key mechanisms of action in the Kaposi Sarcoma pipeline products market are Tubulin Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Fibronectin, Cytotoxic To Cells Expressing Macrophage Mannose Receptor 1, Ephrin Type B Receptor 4 Inhibitor, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha Agonist, Indoleamine 2,3 Dioxygenase 1 Activator, and others.
-
What are the key routes of administration in the Kaposi Sarcoma pipeline products market?
The key routes of administration in the Kaposi Sarcoma pipeline products market are intravenous, subcutaneous, intralesional, intratumor, intravesical, oral, intraperitoneal, intramuscular, intrapleural, intrathecal, and others.
-
What are the key molecule types in the Kaposi Sarcoma pipeline products market?
The key molecule types in the Kaposi Sarcoma pipeline products market are small molecule, fusion protein, monoclonal antibody, synthetic peptide, oncolytic virus, polysaccharide, protein, and recombinant protein.
-
Which are the leading companies in the Kaposi Sarcoma pipeline products market?
Some of the leading companies in the Kaposi Sarcoma pipeline products market are Merck KGaA, Amgen Inc, Aphios Corp, Bristol-Myers Squibb Co, Cannabis Science Inc, Cello Therapeutics Inc, Codiak BioSciences Inc, DAE HWA Pharmaceutical Co Ltd, Eli Lilly and Co, and Galephar Pharmaceutical Research Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Infectious Disease reports